We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tir7.8
Tirzepatide Research
Too few graded studies
133 peer-reviewed studies
What the evidence says
Too few graded studies
Tirzepatide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 1,879 participants.
Based on 133 studies · 42 meta-analyses · 58 RCTs · 69,040 total participants
Confidence
High confidence
By outcome
Weight managementMean weight reductions up to ~21% over 72 weeks in obesity trials — the largest of any approved weight-loss drug to date, superior to semaglutide head-to-head · Months (dose-escalated over ~20 weeks)
Too few graded studies84 studies
Glycemic & metabolic controlLowers HbA1c by roughly 1.9-2.6 percentage points in phase-3 diabetes trials; superior to basal insulin and semaglutide 1 mg head-to-head · Weeks to months · Combined large weight loss and strong glycemic control improve overall metabolic status · Months
Too few graded studies53 studies
Heart & blood pressure
Too few graded studies22 studies
Safety profile
Too few graded studies17 studies
Sleep apnea & respiratory
Too few graded studies5 studies
Active research area
133 studies in the last 5 years · Latest meta-analysis: 2026
20212026
1Meta-Analysis2025
In plain English: Tirzepatide likely results in weight loss at medium-term follow-up, and this initial weight loss is likely to be sustained at longer-term follow-up.
Franco JV, Guo Y, Varela LB, Aqra Z, Alhalahla M, Medina Rodriguez M, Salvador Oscco EL, Patiño Araujo B, Banda S, Escobar Liquitay CM, Bracchiglione J, Meza N, Madrid E. · The Cochrane database of systematic reviews (2025)
Tirzepatide may result in an increase in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 studies, 4582 participants; low-certainty evidence).
The evidence is very uncertain about the effect on serious adverse events (RR 0.99, 95% CI 0.88 to 1.12; 8 studies, 6359 participants; very low-certainty evidence).
Tirzepatide may result in little to no difference in adverse events leading to withdrawal (RR 2.06, 95% CI 1.21 to 3.52; 8 studies, 6359 participants; low-certainty evidence).
In plain English: Further prospective trials are needed to clarify causal mechanisms and inform clinical decision-making.
Liang CS et al. · International journal of molecular sciences (2026)
Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated, and surface under the cumulative ranking curves (SUCRA) were used to estimate relative safety rankings.
Only high-dose tirzepatide (10-15 mg/week) was associated with a significantly increased risk of AKI compared to controls (absolute risk difference: 0.28%; number needed to harm: 357).